- Login
- Manage Portfolio
- Post a StockTalk
- Write an Instablog
- Get Daily Email Alert
-
Seeking Alpha
|
|
| 52wk high: | |
| 52wk low: | |
| EPS: | |
| PE: | |
| Dividend: | |
| Yield: | |
| Market Cap: | |
| Exchange: | |
Articles on Teva Pharmaceutical Industries Ltd. (TEVA)
by latest | most commented
-
Closing Update for Tuesday, July 7
-
Protalix's New Drug Likely to Win FDA Approval
-
Healthcare: Branded Pharma Out, Diagnostics / Generics In
-
Is IBB the Best Biotech ETF?
-
Wednesday's Options Recap
-
Watson Pharmaceuticals Says to Look Ahead to June 2009 Earnings
-
Tylenol Ban Will Hurt Several Drug Manufacturers' Bottom Lines
-
Monday's Closing Update
-
Six Contraception and Birth Control Stocks
-
10 New Stock Indexes for Tracking Healthcare Trends
-
Ending Pay-For-Delay Generic Drug Deals
-
Thoughts on the New World Order: Israel as a Developed Market, S. Korea as an 'Almost'
-
Pharma Announces $80B Reduction: Who Wins?
-
Fortune's 40 Best Stocks to Retire On
-
25 Bullish Option Ideas
-
Passport Capital Chooses Gold over Education
-
Stryker Corp Looks Good for Health Care Rebound
-
Obama's Healthcare Reform: 2 Winners, 2 Losers
-
Israel Says Shalom to Emerging Market Status
-
Is Low Quality Leading the Market?
-
Top 10 ETFs for a Changing Middle East
-
Shumway Beefs Up Teva, Cisco Positions
-
Health Care Trends Part 2: M&A, Generic Competition, CROs
-
Gilead Sciences: Stock in Decline or Great Buying Opportunity?
-
Investment Fund Clones Part III: International ADRs
-
What's John Paulson Buying Now? Hint... Think Gold
-
Harvard's Endowment Stocks Up on Emerging Market ETFs
-
Best Stocks of 2009 Review: The First Third
-
Jim Jubak's Watch List - Should You Own These Stocks?
-
Wall Street Breakfast: Must-Know News
-
Earnings Preview: 5 Companies That Could Surprise
-
Supreme Court Denies Aventis' Cert Petition in Lovenox Case
-
Apple and the QQQ ETF: High-Beta, Growth-Oriented, Tech-Driven Exposure
-
Fast Money Recap - A Hotbed of M&A Activity (4/21/09)
-
First Coverage Weekly Street Sentiment: April 21, 2009
-
CNBC's Fast Money - What to Do About Yahoo? (4/20/09)
-
Impax Labs: Strong Balance Sheet, Focused R&D
-
New MS Therapies: A Hard Pill to Swallow?
-
Opportunities in Healthcare: Highly Defensive Stocks
-
FDA, Clinical Trial Calendar Updates: Theravance, Gilead, Teva, Alnylam, ReNeuron
-
Shumway Capital: Visa Is Top Holding